atorvastatin has been researched along with lactic acid in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Otsuka, Y | 1 |
| Ankola, DD; Chandraiah, G; Kumar, MN; Meena, AK; Rao, PR; Ratnam, DV | 1 |
| Itoh, H; Mitsuishi, M; Miyashita, K; Muraki, A; Tamaki, M; Tanaka, K | 1 |
| Boobalan, R; Choudhury, S; Kandasamy, K; Mishra, SK; Parida, S; Reddy, N; Singh, TU; Singh, V; Sukumarn, SV; Thangamalai, R | 1 |
| Ahmed, TA; Kurakula, M | 1 |
| Ahmed, TA; Alharby, YA; El-Helw, AR; El-Say, KM; Hosny, KM | 1 |
| Allémann, E; Alonso, F; Corpataux, JM; Deglise, S; Delie, F; Dubuis, C; Haefliger, JA; Jordan, O; Mylonaki, I; Saucy, F; Strano, F | 1 |
| Park, K | 1 |
| Abdallah, D; El-Ganainy, SO; El-Khatib, AS; El-Mallah, A; Khattab, MM; Mohy El-Din, MM | 1 |
| Guo, Q; He, J; Jiang, C; Liu, J; Lu, J; Yang, Y; Zhang, W; Zhao, Y | 1 |
| Allémann, E; Delie, F; Durand, M; Jordan, O; Mylonaki, I; Trosi, O | 1 |
| Czapka, A; Fischer, D; Grune, C; Hoeppener, S; Jandt, KD; Neugebauer, U; Scheuer, K; Thamm, J; Werz, O; Zens, C | 1 |
13 other study(ies) available for atorvastatin and lactic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Inhibitory effects of statins on human monocarboxylate transporter 4.
Topics: Animals; Atorvastatin; Basigin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lactic Acid; LLC-PK1 Cells; Lovastatin; Monocarboxylic Acid Transporters; Muscle Proteins; Pyridines; Pyrroles; Simvastatin; Swine; Transfection | 2006 |
Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lactic Acid; Lipids; Male; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrroles; Rats; Rats, Sprague-Dawley | 2008 |
Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance.
Topics: Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactic Acid; Male; Mice; Mice, Inbred C57BL; Mitochondria, Muscle; Muscle Cells; Muscle Strength; Muscle, Skeletal; Organ Size; Oxygen Consumption; Physical Conditioning, Animal; Physical Endurance; Pravastatin; Pyrroles; Ubiquinone | 2012 |
Atorvastatin prevents sepsis-induced downregulation of myocardial β1-adrenoceptors and decreased cAMP response in mice.
Topics: Animals; Atorvastatin; Blotting, Western; Catecholamines; Cyclic AMP; Heptanoic Acids; Lactic Acid; Male; Mice; Myocardium; Pyrroles; Real-Time Polymerase Chain Reaction; Receptors, Adrenergic, beta; Sepsis; Ventricular Function, Left | 2014 |
Co-Delivery of Atorvastatin Nanocrystals in PLGA based in situ Gel for Anti-Hyperlipidemic Efficacy.
Topics: Anticholesteremic Agents; Atorvastatin; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Drug Liberation; Gels; Hyperlipidemias; Lactic Acid; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solvents; Surface Properties; X-Ray Diffraction | 2016 |
Depot injectable atorvastatin biodegradable in situ gel: development, optimization, in vitro, and in vivo evaluation.
Topics: Animals; Atorvastatin; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Carriers; Gels; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intramuscular; Lactic Acid; Male; Microscopy, Electron, Scanning; Phase Transition; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rabbits; Random Allocation; Spectroscopy, Fourier Transform Infrared | 2016 |
Perivascular sustained release of atorvastatin from a hydrogel-microparticle delivery system decreases intimal hyperplasia.
Topics: Animals; Atorvastatin; Carotid Arteries; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Humans; Hyaluronic Acid; Hydrogels; Hyperplasia; In Vitro Techniques; Lactic Acid; Ligation; Male; Mice, Inbred C57BL; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Saphenous Vein; Tissue Distribution; Tunica Intima | 2016 |
Perivascular administration: The outside-in concept.
Topics: Animals; Atorvastatin; Delayed-Action Preparations; Drug Administration Routes; Gels; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperplasia; Lactic Acid; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Tunica Intima | 2016 |
Elucidation of the mechanism of atorvastatin-induced myopathy in a rat model.
Topics: Adenosine Triphosphate; Animals; Atorvastatin; Creatine Kinase; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; L-Lactate Dehydrogenase; Lactic Acid; Male; Microscopy, Electron, Transmission; Mitochondria, Muscle; Motor Activity; Muscle, Skeletal; Muscular Diseases; Myoglobin; Pyruvic Acid; Rats; Rats, Sprague-Dawley; Ubiquinone | 2016 |
Multifunctional Dextran Sulfate-Coated Reconstituted High Density Lipoproteins Target Macrophages and Promote Beneficial Antiatherosclerotic Mechanisms.
Topics: Animals; Atherosclerosis; Atorvastatin; Biological Transport; Cholesterol; Dextran Sulfate; Drug Carriers; Humans; Interleukin-10; Interleukin-6; Intracellular Space; Lactic Acid; Lipoproteins, HDL; Lipoproteins, LDL; Macrophages; Mice; Models, Molecular; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Protein Conformation; RAW 264.7 Cells; Surface Properties; Tumor Necrosis Factor-alpha | 2017 |
Design and characterization of a perivascular PLGA coated PET mesh sustaining the release of atorvastatin for the prevention of intimal hyperplasia.
Topics: Atorvastatin; Caproates; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Liberation; Excipients; Hyperplasia; Lactic Acid; Lactones; Microscopy, Electron, Scanning; Molecular Weight; Polyethylene Terephthalates; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers | 2018 |
Sustainable preparation of anti-inflammatory atorvastatin PLGA nanoparticles.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Chickens; Drug Carriers; Female; Humans; Lactic Acid; Nanoparticles; Particle Size; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2021 |